Globus Medical Inc. (GMED)
Globus Medical, Inc. (GMED) Q1 2025 Earnings Call Transcript
Globus Medical, Inc. (NYSE:GMED ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development & IR Dan Scavilla - President & CEO Keith Pfeil - COO & CFO Conference Call Participants Matt Miksic - Barclays Vik Chopra - Wells Fargo Richard Newitter - Truist Securities Matthew Blackman - Stifel Shagun Singh - RBC Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Craig Bijou - Bank of America Merrill Lynch Matt Taylor - Jefferies Operator Welcome to the Globus Medical's First Quarter 2025 Earnings Call. [Operator Instructions].
Globus Medical (GMED) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates
Globus Medical (GMED) came out with quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.72 per share a year ago.
Gear Up for Globus Medical (GMED) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.
International Growth Drives GMED Stock Amid Fierce Competition
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
GMED Stock May Benefit Following the Acquisition of Nevro
Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
Should You Hold Globus Medical Stock in Your Portfolio Now?
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
